Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine [Yahoo! Finance]
Evommune, Inc. (EVMN)
Company Research
Source: Yahoo! Finance
PALO ALTO, Calif. & NEW YORK, April 06, 2026 BUSINESS WIRE )--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart Tepper, M.D., Vice President, The New England Institute for Neurology and Headache and Professor of Neurology, Geisel School of Medicine at Dartmouth, will discuss the migraine treatment landscape and the unmet need. Greg Dussor, Ph.D. , James Bartlett Chair in Behavioral and Brain Sciences and Professor and Department Head of Neuroscience at the University of Texas – Dallas, will discuss
Show less
Read more
Impact Snapshot
Event Time:
EVMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVMN alerts
High impacting Evommune, Inc. news events
Weekly update
A roundup of the hottest topics
EVMN
News
- Evommune (EVMN) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $48.00 price target on the stock.MarketBeat
- Evommune (EVMN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
- Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in MigraineBusiness Wire
- Evommune (EVMN) was upgraded by Clear Str Llc to "strong-buy".MarketBeat
- Evommune (EVMN) had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
EVMN
Sec Filings
- 4/13/26 - Form 8-K
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- EVMN's page on the SEC website